You're viewing 1 of thousands of funding rounds tracked monthly

Members receive AI-scored leads and instant alerts when companies matching their criteria raise capital. Search all rounds by stage, amount, and investor.

PerkinElmer Invests in Carterra, the Leader in Label-Free High Throughput Antibody Screening and Characterization

Dec 14, 2020•almost 5 years ago

Salt Lake CityPharmaceuticalBiotechnology

Description

Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, today announced that they have closed on a round of equity financing led by PerkinElmer, Inc. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round.

Company Information

Company

Carterra, Inc.

Location

Salt Lake City, Utah, United States

About

Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for biotherapeutic discovery and characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. The new LSA-XT provides enhanced optics to enable additional applications in biotherapeutic discovery and characterization.

Company News

(4 articles)

Tue, 07 Jan 2025 08:00:00 GMT

Carterra Ships Its First Ultra Biosensor Platform and Finishes 2024 with Double-digit Growth and Record Revenues - GlobeNewswire

Wed, 04 Sep 2024 07:00:00 GMT

Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery - PR Newswire

Wed, 20 Apr 2022 07:00:00 GMT

Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services - BioSpace

Fri, 17 Feb 2023 08:00:00 GMT

Structure-free antibody paratope similarity prediction for in silico epitope binning via protein language models - ScienceDirect.com

FundzWatch™ Score

Low Activity

1 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood